Get the Stockscreener App
44.28
1.42%
-0.64
After Hours:
44.60
0.32
+0.72%
Alkermes Plc stock is traded at $44.28, with a volume of 1.52M.
It is down -1.42% in the last 24 hours and up +15.64% over the past month.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
See More
Previous Close:
$44.92
Open:
$45.1
24h Volume:
1.52M
Relative Volume:
0.66
Market Cap:
$7.38B
Revenue:
$1.56B
Net Income/Loss:
$152.72M
P/E Ratio:
49.23
EPS:
0.8994
Net Cash Flow:
$221.80M
1W Performance:
+3.46%
1M Performance:
+15.64%
6M Performance:
+55.37%
1Y Performance:
+43.86%
1-Day Range:
$44.22
$45.71
1-Week Range:
$42.19
$45.76
52-Week Range:
$25.16
$45.76
Alkermes Plc Stock (ALKS) Company Profile
Name
Alkermes Plc
Sector
Phone
00-353-1-772-8000
Address
CONNAUGHT HOUSE, DUBLIN 4
Compare ALKS vs TAK, TEVA, HLN, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
44.28 | 7.38B | 1.56B | 152.72M | 221.80M | 0.8994 |
TAK
Takeda Pharmaceutical Co Adr
|
15.91 | 50.27B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.63 | 40.32B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.13 | 40.31B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
79.57 | 33.36B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
545.96 | 23.17B | 3.17B | 1.29B | 1.01B | 27.09 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-24-26 | Initiated | Wolfe Research | Outperform |
| Nov-11-25 | Initiated | Truist | Buy |
| Sep-26-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Sep-03-25 | Initiated | Wells Fargo | Overweight |
| Jul-15-25 | Initiated | Goldman | Buy |
| Jun-17-25 | Upgrade | UBS | Neutral → Buy |
| May-28-25 | Initiated | Needham | Buy |
| Mar-13-25 | Initiated | RBC Capital Mkts | Sector Perform |
| Mar-04-25 | Upgrade | UBS | Sell → Neutral |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Nov-05-24 | Upgrade | Stifel | Hold → Buy |
| Jun-17-24 | Initiated | TD Cowen | Buy |
| Mar-19-24 | Initiated | Robert W. Baird | Outperform |
| Feb-20-24 | Downgrade | UBS | Neutral → Sell |
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Oct-24-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-17-23 | Initiated | UBS | Neutral |
| Nov-03-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-14-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-16-22 | Initiated | Piper Sandler | Neutral |
| Apr-22-22 | Resumed | Goldman | Buy |
| Apr-20-22 | Initiated | Goldman | Buy |
| Jan-27-22 | Upgrade | Cantor Fitzgerald | Hold → Overweight |
| Dec-01-21 | Initiated | Citigroup | Neutral |
| Oct-07-21 | Upgrade | Jefferies | Hold → Buy |
| Sep-02-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Oct-15-20 | Upgrade | Mizuho | Neutral → Buy |
| Jul-30-20 | Downgrade | Goldman | Neutral → Sell |
| Feb-14-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Feb-14-20 | Reiterated | H.C. Wainwright | Neutral |
| Feb-14-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Jan-31-20 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Sep-05-19 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jul-15-19 | Upgrade | Goldman | Sell → Neutral |
| May-31-19 | Initiated | H.C. Wainwright | Neutral |
| May-01-19 | Downgrade | Citigroup | Buy → Neutral |
| Dec-19-18 | Downgrade | Goldman | Neutral → Sell |
| Dec-14-18 | Initiated | Wolfe Research | Underperform |
| Dec-13-18 | Downgrade | Credit Suisse | Outperform → Underperform |
| Nov-05-18 | Initiated | Piper Jaffray | Neutral |
| Aug-07-18 | Initiated | Stifel | Hold |
| Jun-21-18 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jun-06-18 | Initiated | B. Riley FBR, Inc. | Buy |
| May-16-18 | Upgrade | Citigroup | Neutral → Buy |
| May-11-18 | Initiated | BofA/Merrill | Buy |
View All
Alkermes Plc Stock (ALKS) Latest News
Why (ALKS) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Insider Sell: Christopher Wright Sells 2,000 Shares of Alkermes PLC (ALKS) - GuruFocus
Alkermes (ALKS) director sells 2,000 shares under Rule 10b5-1 plan - Stock Titan
Alkermes plc (ALKS) Rule 144 notice: 2,000 vested RSU shares listed - Stock Titan
Alkermes' alixorexton gains FDA orphan drug status for idiopathic hypersomnia - MSN
Alkermes (ALKS) Receives FDA Orphan Designation for Alixorexton - GuruFocus
Alkermes (ALKS) Receives Orphan Drug Designation for Alixorexton - GuruFocus
Alkermes touts orexin ambitions as Alixorexton enters phase 3 and CEO transition nears - MSN
Alkermes Touts Orexin Ambitions as Alixorexton Enters Phase 3 and CEO Transition Nears - Yahoo Finance
ALKS: Orexin agonist program advances with strong clinical data, strategic acquisition, and leadership transition - TradingView
ALKS: Orexin agonist advances, Avadel integration, and pipeline expansion drive strategic momentum - TradingView
Alkermes stock hits 52-week high at 44.58 USD By Investing.com - Investing.com Australia
Alkermes PLC (ALKS) Shares Surge 4.4% -- What GF Score of 74 Tel - GuruFocus
Alkermes Jumps 5.6% After RBC Capital Maintains Outperform - AlphaStreet
Alkermes stock hits 52-week high at 44.58 USD - Investing.com
ALKS Maintained by RBC Capital -- Price Target Raised to $56.00 - GuruFocus
Alkermes' Orexin May Have Applicability Outside Sleep, RBC Says - marketscreener.com
RBC Capital raises Alkermes stock price target on pipeline potential By Investing.com - Investing.com South Africa
RBC Capital raises Alkermes stock price target on pipeline potential - Investing.com India
RBC Raises Price Target on Alkermes to $56 From $45, Keeps Outperform Rating - marketscreener.com
Alcohol Use Disorder Market Set to Expand at a 12.1% CAGR During the Forecast Period (2026–2036), Owing to the Emergence of Novel Mechanisms Such as 5-HT3 Pathway, NOP Receptor, mGluR5 NAM, and Other | DelveInsight - GlobeNewswire Inc.
ALKS Q1 2026 Earnings: EPS Surpasses Expectations Despite Net LossEarnings Beat Alert - newsline.com
Alkermes Plc (ALKS) Stock Analysis: Strong Buy Ratings And Promising Growth Potential - DirectorsTalk Interviews
Alkermes to participate in the Goldman Sachs 47th annual global healthcare conference - MSN
Should Alkermes’ Stronger Q1 2026 Results and Sleep-Medicine Advances Prompt Action From ALKS Investors? - Yahoo Finance
Alkermes to present new data on Alixorexton and LUMRYZ® (sodium oxybate) at SLEEP 2026, highlighting breadth of sleep medicine research - MSN
Alkermes Public Limited Company Trade Ideas — XETR:8AK - TradingView
Healthcare ETFs: PJP Focuses on Pharmaceuticals, While XBI Zeroes in on Biotech - The Motley Fool
Insider Sell Alert: David Gaffin Sells Shares of Alkermes PLC - GuruFocus
ALKS Stock Surges 15% On Lilly-Centessa Buyout Igniting Sleep Pipeline Hopes - Stocktwits
Alkermes (ALKS) Showcases Sleep Medicine Research at SLEEP 2026 - GuruFocus
Alkermes (ALKS) EVP Gaffin sells 2,034 shares under 10b5-1 plan - Stock Titan
[144] Alkermes plc. SEC Filing - Stock Titan
Alkermes plc (ALKS) Stock Price, News, Quote & History - Yahoo Finance
Alkermes to Present Sleep Medicine Research at SLEEP 2026 - GuruFocus
Alkermes (ALKS) Up 21.1% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Alkermes to present narcolepsy drug data at SLEEP 2026 By Investing.com - Investing.com South Africa
Alkermes to present narcolepsy drug data at SLEEP 2026 - Investing.com
New narcolepsy and hypersomnia treatment data from Alkermes at SLEEP 2026 - Stock Titan
Alkermes PLC (ALKS) Shares Surge 3.5% -- What GF Score of 75 Tel - GuruFocus
ALKS Stock Price, Quote & Chart | ALKERMES PLC (NASDAQ:ALKS) - ChartMill
Alkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference - Business Wire
Is Alkermes’ (ALKS) New LYBALVI Real-World Data Quietly Reframing Its Psychiatry Investment Story? - simplywall.st
Understanding Momentum Shifts in (ALKS) - Stock Traders Daily
ALKS Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive SurpriseEstimate Revision Count - newsline.com
Alkermes (NASDAQ: ALKS) CMO sells 9,000 shares, exercises 5,000 options under 10b5-1 plan - Stock Titan
Craig Hopkinson sells three 9,000-share tranches at Alkermes (NASDAQ: ALKS) - Stock Titan
Alkermes plc (ALKS) Stock Analysis: Solid Growth Potential with 28.2% Revenue Surge and Analyst Consensus - DirectorsTalk Interviews
Alkermes Insider Sold Shares Worth $687,007, According to a Recent SEC Filing - marketscreener.com
Tranche Update on Alkermes plc's Equity Buyback Plan announced on February 15, 2024. - marketscreener.com
What Does the Recent Insider Sale by Alkermes' VP of Finance Signify - Kavout
Alkermes Plc Stock (ALKS) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.37%
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):